Citizen petition asks FDA not to allow compounding of the seven peptides reviewed by its July advisory committee

Summary. The Partnership for Safe Medicines (PSM), a drug-safety advocacy group, has filed a citizen petition asking FDA not to allow compounding with any of the seven peptide bulk drug substances its Pharmacy Compounding Advisory Committee (PCAC) considered on 23-24 July 2026. The petition, filed under 21 CFR 10.30 and marked as submitted via Regulations.gov on 23 October, asks FDA to refrain from doing so by regulation, by adding the substances to Category 1 of its 503A interim policy, or through enforcement discretion. It also asks FDA not to rely on the July meeting for the advisory-committee consultation that section 503A requires before the 503A bulks list can be changed.

Research context (RUO). The petition summarizes the July record this way: FDA's own reviewers recommended against all seven substances, while the committee voted to recommend six of them and against one. PSM argues that the committee was constituted in violation of the Federal Advisory Committee Act and the Ethics in Government Act, citing what it describes as members' financial ties to the peptide industry; those are the group's allegations, and FDA has not ruled on them. FDAWeb reported the filing on 22 October and noted that it coincides with the interim peptide access policy now under White House review, whose text has not been published. PSM's first argument concerns physical and chemical characterization. In the briefing excerpts the petition quotes, FDA reviewers linked a substance being "not well characterized" to missing data on its identity, purity and impurity profile. Those are the same three categories a lot-level certificate of analysis reports, and FDA's 503A page separately requires every bulk drug substance used by a 503A compounder to be accompanied by a valid certificate of analysis and made by an FDA-registered establishment. In a separate post, PSM says it obtained compounded peptide products from four state-licensed pharmacies in Texas and Pennsylvania that were shipped to California within 45 days, and that it could not find some of the California licenses it says were required. PSM says the products are the subject of complaints with state boards of pharmacy and FDA; none of those bodies has published findings. A citizen petition is a request, not an FDA decision, and the substances' status does not change unless the agency acts.

Related: FDA Peptide Compounding Policy Tracker 2026, a sourced status page for the interim notice, the July advisory votes and the 503A bulks list.

This summary is for research-community awareness only and is not legal advice. For research use only. Not for human or veterinary use.